Heart transplantation replaces a diseased heart with a donor heart, with the aim of improving survival and quality of life in selected patients with advanced heart disease that cannot be adequately controlled by other treatments. The usual procedure is orthotopic transplantation, in which the organ is implanted in the anatomical position of the native heart. Outcomes depend on the entire care pathway: timely identification of candidates, management while waiting, organ selection, myocardial protection, surgical technique and lifelong surveillance. Surgery corrects the cardiac component of the disease but does not reverse any irreversible extracardiac damage and requires continuous immunosuppressive treatment.
In adults, ischaemic heart disease and non-ischaemic cardiomyopathies are major indications; in children, congenital heart disease and cardiomyopathies carry greater weight. Other candidates have restrictive physiology, advanced hypertrophic cardiomyopathy, refractory arrhythmias or disease of a previous allograft. Transplant volumes reflect organ availability and access to care as well as disease prevalence. In the US OPTN/SRTR report for 2023, published in 2025, five-year adult survival was 80.3%; this figure describes a defined population and time cohort and is not a prediction that applies indiscriminately to individual recipients.
The duration of benefit is influenced by different problems at different stages. Initially, early graft function and surgical complications predominate; later, rejection, infection, drug toxicity and cardiac allograft vasculopathy become central. Expanding donation options, preservation technologies and more refined surveillance may improve the pathway, but must be assessed against clinical evidence, donor characteristics and recipient needs. Transplantation remains a highly specialised treatment for a chronic disease, accompanied by new physiology and new immunological vulnerability.
The most common indication arises from progressive pump failure that persists despite appropriate medical and interventional treatment. In ischaemic heart disease, infarction scars, residual ischaemia and remodelling may leave too little recoverable myocardium. In dilated cardiomyopathies, genetic variants, toxicity, inflammation or other causal factors may cause diffuse damage to cardiomyocytes and the extracellular matrix. The final phenotype may look similar, but the potential for recovery differs: a genetically determined disease with extensive fibrosis, tachycardia-induced cardiomyopathy and recent dysfunction after myocarditis must not be regarded as equivalent. Before choosing transplantation, it is necessary to establish which components of the disease remain treatable.
Severity does not necessarily correspond to a low ejection fraction. In restrictive forms, a small, poorly compliant ventricle may maintain an apparently preserved ejection fraction despite a reduced stroke volume and very high filling pressures. Hypertrophic cardiomyopathy may likewise progress to advanced failure with or without a marked reduction in systolic function. Infiltrative diseases require consideration of the systemic component: in amyloidosis, the amyloid type, disease control and extracardiac involvement fundamentally alter candidate selection. Heart replacement may be appropriate in selected patients but does not automatically stop production or deposition of the responsible protein.
Congenital heart disease poses distinct challenges. Previous operations, collateral vessels, unconventional vascular anatomy and end-organ abnormalities may complicate both the waiting period and implantation. In failure of the Fontan circulation, for example, dysfunction may arise from the interaction of high systemic venous pressure, restricted pulmonary blood flow, ventricular dysfunction and hepatic or lymphatic complications. Systolic function that is not severely depressed does not exclude end-stage disease. Defining anatomy and reversibility of liver injury also helps assess whether a combined transplant programme is required, rather than automatically applying criteria developed for adult dilated heart failure.
Another group comprises patients with refractory ventricular arrhythmias. When tachycardia or fibrillation recurs despite drug treatment, ablation and appropriate devices, the threat to survival may be high even in the absence of persistent congestion. An indication requires evidence of refractoriness and assessment of options for controlling the arrhythmogenic substrate. Less commonly, intractable angina in non-revascularisable heart disease may contribute to assessment; coronary pain or a complex stenosis alone is not sufficient justification. The objective remains to identify a cardiac risk or disability that transplantation can effectively modify.
The pathophysiological rationale is to restore adequate cardiac output and filling pressures compatible with the function of other organs. When renal congestion, reduced hepatic perfusion and deconditioning are still predominantly functional, haemodynamic correction may lead to substantial recovery. By contrast, advanced structural kidney disease, cirrhosis or severe vascular disease are not resolved simply by implanting a new heart. Selection therefore depends on extracardiac reversibility and on the risk that surgery, cardiopulmonary bypass and subsequent medication will aggravate established damage. This assessment explains why early referral is preferable to referral only after multiorgan failure has developed.
Transplant candidacy is also dynamic. An obstacle may be temporary, such as a treatable infection, correctable malnutrition or pulmonary hypertension that decreases after left ventricular unloading; other conditions entail persistently high risk. Mechanical ventricular assistance may support a patient while awaiting transplantation or enable reassessment after organ function improves. Temporary support may instead provide time to clarify reversibility and neurological integrity in shock. The strategy must specify the patient's foreseeable destination and the circumstances that would justify changing it, so that an initially temporary solution does not continue without a defined goal.
The donor heart expresses antigens different from those of the recipient, particularly molecules of the HLA system. Allograft recognition activates innate and adaptive pathways that can injure the myocardium and vascular compartment. In direct recognition, recipient T lymphocytes interact with allogeneic HLA molecules presented by donor cells; in indirect recognition, donor antigens are processed and presented by recipient cells. The intensity and duration of the response depend on immunological memory, antigen exposure, inflammation and the effectiveness of immunosuppression. Stable spontaneous tolerance of the organ is not the usual outcome of the clinical procedure.
Lymphocyte activation requires antigen recognition, costimulatory signals and mediators that sustain proliferation and differentiation. Increased intracellular calcium activates calcineurin, promoting the activity of the NFAT transcription factor and production of interleukin-2; mTOR-dependent pathways participate in the proliferative response. Cytotoxic lymphocytes can injure cardiomyocytes, while helper lymphocytes and antigen-presenting cells amplify the response. These steps explain why drugs with different targets are combined: blocking several points in the response provides more effective protection than indefinitely increasing the dose of one medication.
Antibodies may already be present or may develop after transplantation. Pregnancy, transfusions and previous transplants are important sensitising events; a history of mechanical circulatory support and related procedures may also be associated with a more complex immunological profile. Donor-specific antibodies, or DSA, may bind to graft endothelium, activate complement, effector cells and inflammatory signalling, and promote microvascular injury. The presence of DSA alone does not establish a diagnosis of active rejection, and their absence from the blood does not exclude every form of antibody-mediated injury. Clinical assessment requires integration with cardiac function, histology and immunopathology.
Procurement and implantation involve a period of ischaemia followed by reperfusion. ATP depletion, calcium abnormalities and oxidative stress can cause transient dysfunction or irreversible injury, with endothelial activation and recruitment of inflammatory cells. This process may amplify organ immunogenicity but must not automatically be equated with rejection. Primary graft dysfunction, now considered within the classification of early dysfunction of the 2026 ISHLT consensus, is distinguished from presentations attributable to a specific cause, such as hyperacute rejection, surgical obstruction or excessive pulmonary afterload. This distinction has practical consequences, because intensifying immunosuppression will not correct an obstructed anastomosis or cardiac tamponade.
Denervation changes regulation of the transplanted heart. Loss of vagal tone favours a relatively high resting heart rate; during exercise, the chronotropic response initially depends mainly on circulating catecholamines and is slower, with similarly delayed heart-rate recovery. The increase in cardiac output relies substantially on the Frank–Starling mechanism. Some reinnervation may occur over time, but it varies and does not necessarily restore a normal response. Sensory denervation may reduce the perception of ischaemia, allowing coronary events without typical angina; vascular surveillance is therefore important even in asymptomatic patients.
The donor's right ventricle encounters a pulmonary circulation different from its original one. If the recipient's resistance is elevated, the new ventricle may dilate and become less efficient, causing systemic congestion and reduced left ventricular filling. Myocardial oedema, ischaemic times and interaction with ventilation may further accentuate early vulnerability. Haemodynamic recovery must be interpreted alongside preload, afterload, rhythm and function of both ventricles. Over the long term, immune and non-immune endothelial injury, intimal proliferation and microcirculatory abnormalities contribute to vasculopathy, while immunosuppression may alter metabolism, renal function and infectious risk. The recipient's physiology therefore remains the product of continuous interaction among the organ, immune system and treatment.
The clinical pathway begins with the history of cardiac disease and its response to treatment. Onset, aetiology, hospital admissions, arrhythmias, interventions, need for inotropes and changes in functional capacity are reconstructed. Patients may report dyspnoea on minimal exertion, orthopnoea, extreme fatigue, early satiety or inability to perform usual activities. In other cases, syncope, electrical storms or low-output limitation with relatively little congestion predominate. It is necessary to clarify which symptoms persist despite maximally tolerated treatment and which are due to correctable conditions. A severely reduced ejection fraction in a clinically stable person does not automatically mandate transplantation.
The extracardiac history identifies renal, hepatic, respiratory and vascular diseases, previous malignancies, infections, metabolic disorders and surgical procedures. Details of previous transfusions, pregnancies and any transplants are important because they may change the likelihood of sensitisation. Environmental exposures, travel or geographical origin guide infectious disease investigations. Medication review includes immunomodulators, non-prescription products and substances that could interfere with later therapies. The interview must also clarify adherence, tobacco or other substance use and practical barriers to follow-up, distinguishing modifiable problems from persistent conditions.
Physical examination proceeds from perfusion and respiratory status to a full cardiovascular assessment. Blood pressure, heart rate, skin temperature, capillary refill and alertness help identify hypoperfusion. Jugular venous distension, hepatojugular reflux, hepatomegaly, ascites and oedema describe venous congestion; cardiac and pulmonary auscultation and pulse examination reveal additional findings. Looking for signs of infection, skin lesions and dental problems is particularly important before immunosuppression. Findings should be compared with usual body weight and fluid balance, as oedema and cachexia may coexist.
Assessment of frailty encompasses strength, mobility, fatigability, weight loss and the ability to perform activities of daily living. Impairment predominantly related to heart failure may improve with rehabilitation, nutrition or circulatory support, whereas severe limitation due to neurological or musculoskeletal disease may persist after transplantation. Chronological age is not synonymous with frailty. Similarly, cognitive impairment calls for an assessment of actual abilities and available support, rather than reducing eligibility to a diagnostic label. The clinical question is whether the care pathway can be followed reliably and yield a proportionate benefit.
The specialist consultation explores expectations, understanding and priorities. Patients need to know that joining the waiting list does not guarantee an organ within a predictable period, that their course may require mechanical support and that good function of the transplanted heart does not permit medications to be stopped. The possibility of deterioration while waiting and the limitations of treatments must be discussed before an emergency arises. Involving caregivers helps organise transport, medications, appointments and responses to warning signs while preserving the patient's decision-making autonomy. This preparation is a clinical component of treatment because it directly affects continuity of care.
Transplantation does not have “diagnostic criteria” for a disease of the same name: it requires a candidacy assessment based on the cardiac diagnosis, prognosis and procedural risk. According to the 2024 ISHLT guidelines, the decision integrates cardiac severity, potential improvement with alternative treatments, comorbidities, functional status and capacity to sustain follow-up. Echocardiography defines systolic and diastolic function, chamber dimensions, valves and right-heart status. ECG, rhythm monitoring and, where appropriate, device interrogation establish the arrhythmia burden. Initial tests include complete blood count, electrolytes, renal and hepatic function, blood glucose, lipid profile and further investigations guided by the clinical picture.
Aetiological characterisation precedes labelling a condition irreversible. Coronary assessment clarifies whether revascularisation is an option; magnetic resonance imaging can differentiate injury patterns and quantify fibrosis; genetic testing contributes in appropriate cardiomyopathies and may also inform family care. Myocardial biopsy is reserved for situations in which its results may change treatment, such as certain inflammatory or infiltrative disorders. In congenital heart disease, computed tomography and magnetic resonance imaging delineate vessels, connections, collaterals and relationships with previous prostheses. The aim is not to accumulate tests but to answer questions that alter the indication, surgical strategy or risk.
In stable outpatients, cardiopulmonary exercise testing documents exercise limitation and contributes to prognostic assessment. Very low peak oxygen uptake supports an indication, but must be interpreted in light of beta-blocker treatment, age, sex, weight and achievement of adequate effort. Percentage of the predicted value and the VE/VCO2 slope help contextualise the result; a slope greater than 35 is an adverse prognostic feature, particularly when exercise is submaximal. No single threshold replaces comprehensive evaluation. In an unstable patient unable to discontinue inotropes or experiencing shock, insisting on exercise testing may be inappropriate and must not delay decisions.
Right-heart catheterisation measures right atrial pressure, pulmonary pressures, wedge pressure and cardiac output. Pulmonary vascular resistance is calculated by dividing the difference between mean pulmonary arterial pressure and wedge pressure by cardiac output; reliable output measurement is therefore essential. Interpretation distinguishes passive pressure elevation from a vascular component and takes ongoing treatment into account. If findings are unfavourable, decongestion, vasoactive drugs and selected reversibility testing allow risk to be reassessed. A reduction achieved only at the cost of marked systemic hypotension does not represent a reassuring response. When necessary, unloading with an LVAD may allow reassessment at a later stage.
For the kidneys, persistence of dysfunction after haemodynamic optimisation, proteinuria and structural changes help identify intrinsic nephropathy. Creatinine is interpreted in relation to muscle mass and trends over time; in uncertain cases additional methods for measuring filtration may be needed. Liver assessment combines laboratory tests, imaging and, in selected circumstances, invasive investigations to distinguish reversible congestion from advanced injury. Severe irreversible dysfunction may point to combined heart–kidney or heart–liver transplantation, where appropriate, or render the procedure disproportionate. The decision does not follow from a single laboratory value or the mere presence of a comorbidity.
Infectious disease investigations establish the candidate's status for CMV, EBV, hepatitis viruses, HIV, toxoplasma and other relevant pathogens, with tests for latent or endemic infections added according to risk. An uncontrolled active infection may make immunosuppression dangerous; a well-controlled chronic infection does not automatically mean exclusion from the programme. Managing an LVAD-related infection requires specific reasoning, since transplantation may remove some infected material but exposes the patient to dissemination if control is inadequate. Vaccinations and treatment of infectious foci should, as far as possible, be planned before surgery, when the immune response is generally better.
Oncological assessment considers the type, stage, biology and treatment of any previous malignancy, together with the risk of recurrence under immunosuppression. Fixed intervals applied identically to every tumour do not constitute adequate individual assessment. Age- and risk-appropriate screening and targeted investigations complete the picture, avoiding confusion between a remote cancer history and active high-risk disease. Glycaemic control, obesity, cerebrovascular disease, peripheral arterial disease and respiratory function are assessed in parallel. The goal is to estimate whether a non-cardiac condition will limit survival or prevent meaningful functional recovery even after a successful operation.
ABO and HLA typing and anti-HLA antibody testing define the compatibility profile. Single-antigen assays identify antibody specificities and antigens considered unacceptable. The calculated panel-reactive antibody represents the estimated proportion of potentially incompatible donors in the reference population, not the probability, expressed as a percentage, that the heart will be rejected. Fluorescence intensity in these assays is semiquantitative and affected by analytical conditions; a numerical result must not be converted into a universal biological threshold. Specificities must be reassessed after sensitising events and in light of the candidate's history.
The virtual crossmatch compares known recipient antibodies against donor typing; a physical crossmatch detects serum reactivity against donor cells using defined techniques. The choice depends on risk, the quality and currency of immunological information and time available. Highly sensitised candidates may face greater difficulty while waiting and require a specific strategy, sometimes including desensitisation. This does not remove all risk and involves exposure to therapies with potential toxicity and infection. Assessment culminates in a multidisciplinary decision defining eligibility, any conditions requiring correction and the need for reassessment, whereas urgency and allocation follow the relevant transplant system.
While waiting, useful and tolerated therapies are continued, with reassessment of congestion, rhythm, renal and hepatic function and functional capacity. Rehabilitation and nutritional support aim to preserve physiological reserve. Deterioration may require hospital admission, inotropes or circulatory support; sustained improvement may instead alter urgency or even the need for transplantation. Listing is therefore not an immutable state. Infections, new tumours or neurological events may also lead to suspension and reassessment of candidacy. When an organ becomes available, the decision must reflect the current clinical picture rather than a snapshot obtained months earlier.
Donor selection integrates blood-group and immunological compatibility, heart dimensions, organ quality and infectious risk. Size matching cannot be reduced to body weight: predicted heart mass helps identify an organ relatively undersized for recipient needs, particularly when pulmonary afterload is high. Donor age, hypertrophy, ventricular function, clinical history and anticipated ischaemic times are considered together. A single unfavourable feature does not represent overall risk, and a less-than-optimal organ may be reasonable for a candidate facing a very high risk of dying while waiting. Acceptance requires an explicit balance of these competing risks.
With donation after determination of death by neurological criteria, the organ may be affected by the donor's catecholaminergic and inflammatory response and haemodynamic changes before procurement. Initial dysfunction may be reversible; repeat assessment and donor management help distinguish it from significant heart disease. Donation after determination of death by circulatory criteria instead introduces a period of warm ischaemia and requires specific recovery, assessment and preservation pathways. In the randomised study by Schroder and colleagues, hearts donated after circulatory death, resuscitated and assessed using extracorporeal perfusion, achieved six-month survival non-inferior to that in the prespecified comparator group. Implementation depends on protocols and programme circumstances.
Organ preservation must limit metabolic injury between procurement and reperfusion. Hypothermic static storage lowers energy demand but does not completely halt ischaemic processes; duration, temperature and cardioplegia quality remain critical. Ex situ perfusion systems provide controlled perfusion, sometimes at normothermia, and allow data to be obtained on organ function or metabolism. The technologies are not interchangeable, and perfusion measurements alone cannot guarantee freedom from dysfunction after implantation. Transport times, reconstruction requirements and difficulties in explanting the native heart must be planned together because they affect total graft exposure time.
In orthotopic transplantation, the recipient is placed on cardiopulmonary bypass and the native heart is removed while preserving structures required for anastomoses. The bicaval technique connects the superior and inferior venae cavae separately and preserves the anatomy of the donor's right atrium more faithfully than the biatrial technique. Connections to the left atrium, pulmonary artery and aorta are also created. Technique selection takes anatomy, previous surgery and reconstruction needs into account; distortion, tension and twisting of anastomoses may compromise outcomes. Careful de-airing and echocardiographic inspection accompany restoration of blood flow. Heterotopic transplantation, which leaves the native heart in place, now has very limited applications and is not the standard procedure.
Reperfusion is followed by assessment of biventricular function and loading conditions. Weaning from cardiopulmonary bypass requires adequate output and pressure, rhythm control, haemostasis and the absence of mechanical obstruction. Inotropes, vasopressors, temporary pacing and, when indicated, pulmonary vasodilators are adjusted to the predominant defect. A dilated right ventricle, an underfilled left ventricle and global dysfunction require different interpretations. Failure to wean must not immediately be attributed to nonspecific cardiac “weakness”: tamponade, anastomotic abnormalities, ischaemia, increased pulmonary afterload and immunological incompatibility must be investigated, with mechanical support initiated when perfusion remains inadequate.
Postoperatively, haemodynamic monitoring, echocardiography and serial tests guide fluid management, ventilation and pharmacological support. The balance is delicate: the right ventricle may need sufficient preload without tolerating volume overload, while the kidneys must recover after an operation combining ischaemic and congestive risks. Bleeding, coagulopathy and transfusion requirements are addressed with sensitisation and infectious risk also in mind. Progressive mobilisation and nutritional recovery begin as soon as stability permits. Treatment goals extend beyond extubation or intensive care discharge to recovery of sustainable independence and preparation for graft management.
Immunosuppression consists of induction, maintenance and treatment of rejection episodes, with choices tailored to risk. Induction uses biological agents in selected patients; it may be considered for high immunological risk or to allow a more cautious introduction of calcineurin inhibitors in the presence of renal dysfunction. Antithymocyte globulins cause lymphocyte depletion, whereas basiliximab interferes with the interleukin-2 receptor. Efficacy and toxicity differ: cytopenias, infusion reactions and infections must be balanced against expected benefit. There is no requirement to use the same induction regimen in every recipient, and omission of induction does not mean a lack of immunosuppressive protection.
Maintenance often includes a calcineurin inhibitor, an antimetabolite and corticosteroids, with subsequent adjustments. Tacrolimus binds to FKBP12, and the complex inhibits calcineurin; ciclosporin acts by binding to cyclophilin. Both limit lymphocyte activation but may cause nephrotoxicity, hypertension and drug interactions. Tacrolimus may promote glucose abnormalities and neurotoxicity; ciclosporin has a different metabolic and adverse-effect profile. Drug selection and exposure are adjusted to the patient. Blood concentrations are an essential tool, but do not replace assessment of renal function, toxicity and rejection risk.
Mycophenolate inhibits inosine monophosphate dehydrogenase and reduces de novo purine synthesis, which is particularly important for lymphocyte proliferation. Gastrointestinal disturbances, leukopenia and other cytopenias may limit its use; toxicity and infection must be distinguished before changing treatment. Azathioprine is an alternative in selected situations, with a different metabolic and interaction profile. Corticosteroids have broad anti-inflammatory and immunosuppressive transcriptional effects; their cumulative exposure is reduced over time where possible to limit diabetes, osteoporosis, myopathy and other complications. Complete withdrawal is an individual decision and should not be regarded as an inevitable step for every recipient.
Sirolimus and everolimus inhibit mTOR and interfere with cell proliferation. They may be useful in strategies intended to reduce calcineurin-inhibitor exposure or limit vasculopathy, but their use requires attention to wound healing, oedema, dyslipidaemia, proteinuria, cytopenias and non-infectious pneumonitis. Conversion too early or withdrawal of the previous therapy without adequate cover can increase other risks. Potential renal benefit must be assessed against the type of kidney disease and the presence of proteinuria. The structure of the immunosuppressive regimen is thus changed according to specific problems, not a universal hierarchy of inherently better or worse drugs.
Therapeutic drug monitoring must account for sampling time, formulation and the interval since the last dose. Many immunosuppressants are substrates of CYP3A and transporters such as P-glycoprotein: azole antifungals, certain antibiotics and antivirals, anticonvulsants and herbal products can substantially change exposure. Diarrhoea, organ failure and formulation changes may also alter concentrations. Medication reconciliation is therefore necessary with each new prescription and hospital admission. Adherence concerns not only taking medication but also regular dosing times, reporting adverse effects and understanding what to do if a dose is missed or vomited.
Rejection surveillance combines clinical examination, ECG, echocardiography, laboratory testing, DSA assessment and endomyocardial biopsy according to post-transplant stage and risk. Echocardiography can identify dysfunction and changes over time, but normal systolic function does not exclude early rejection. Biopsy can characterise cellular infiltration and myocyte injury and, with appropriate investigations, the antibody-mediated component. Results must be interpreted in relation to sample quality and representativeness. Surveillance programmes are more intensive early on and after significant episodes, treatment changes or adherence problems, without allowing a standard schedule to replace clinical judgement.
Gene-expression profiling and donor-derived cell-free DNA have expanded non-invasive monitoring options. The former may help rule out significant cellular rejection in selected low-risk populations within validated intervals and conditions. The latter measures a signal of organ injury rather than a specific signature of a single cause: an increase requires interpretation and further investigation, whereas a low result is meaningful in relation to context and assay performance. The IMAGE study and multicentre D-OAR study contributed to the evidence base for these strategies. Neither tool justifies delaying urgent investigations in a patient with new haemodynamic dysfunction.
Rejection treatment depends on type, grade and clinical consequences. Mild asymptomatic cellular episodes may require different management from rejection accompanied by dysfunction or haemodynamic compromise. High-dose corticosteroids and, in appropriate settings, lymphocyte-depleting therapies are used according to risk and response. Antibody-mediated rejection may require strategies to remove antibodies, limit their production or reduce their effects. The choice among plasmapheresis, immunoglobulins and other specialist treatments is not based on antibody positivity alone. In every episode, inadequate drug exposure, interactions, absorption problems and non-adherence must be investigated.
Infection prevention is individualised. CMV risk also depends on donor–recipient serological status, with particular vulnerability in seronegative recipients receiving an organ from a seropositive donor. Prophylaxis and monitoring are adapted to this profile and to immunosuppression intensity. Prevention of Pneumocystis jirovecii infection preferentially uses trimethoprim–sulfamethoxazole when tolerated, with alternatives in appropriate cases. Toxoplasma and EBV status, vaccinations and possible exposures complete the strategy. After intensive treatment for rejection, infection risk changes again: it must not be estimated simply by counting the months since surgery.
Long-term protection includes control of blood pressure, glucose and lipid metabolism, bone health measures, cancer screening and skin care. Statins have a role after transplantation partly because of evidence of beneficial graft outcomes, with drug and dose selected in light of interactions. The landmark pravastatin study helped establish this approach, while later recommendations incorporate individual risk and other lipid-lowering options. Vasculopathy surveillance uses selected anatomical or functional methods according to the programme, time since surgery and renal function; monitoring symptoms alone is insufficient. Rehabilitation should include warm-up and recovery appropriate to chronotropic responses and address muscular deconditioning.
Reproductive health requires specialist planning. Mycophenolate is teratogenic, and a planned pregnancy necessitates advance review of the regimen together with assessment of graft function, immunological stability and comorbidities. Contraception and the safety of concomitant medications should also be discussed. In children and adolescents, growth, development, schooling and transfer to adult services are components of follow-up; transition may be a period of particular vulnerability to treatment interruption. Psychological support addresses fear of rejection, the experience of transplantation and adaptation to everyday life, which may persist even when cardiac function is satisfactory.
Prognosis varies with preoperative condition, donor characteristics, early events and later complications. Surviving the perioperative phase improves the outlook, but risk does not disappear: vasculopathy, malignancy, infections and kidney failure become increasingly important. Survival conditional on having reached a given time point differs from survival calculated from the operation, and data from different registries are not automatically comparable. Retransplantation may be discussed in selected cases, considering the cause of failure, time since the first procedure and overall condition. Tolerance strategies, new preservation methods and xenotransplantation are research areas at differing stages of maturity; they cannot be presented as routine alternatives to established clinical transplantation.
Early bleeding and coagulopathy may result from the combination of complex surgery, cardiopulmonary bypass, hypothermia, consumption of clotting factors and previous treatments. Major haemorrhage reduces perfusion and may require transfusion or surgical revision; a compressive pericardial effusion instead obstructs filling and can mimic graft dysfunction. Postoperative tamponade may be localised and lack all the classic signs. Anatomical and echocardiographic assessment must accompany haemodynamic evaluation, because correction requires treatment of the mechanical cause, not merely increased pharmacological support.
Early left, right or biventricular dysfunction may prevent separation from cardiopulmonary bypass or emerge after initial stabilisation. Distinguishing graft injury without an identifiable secondary cause from failure related to pulmonary hypertension, ischaemia or surgical problems guides support. Vasoplegia may occur with relatively preserved ventricular function and coexist with pump failure, producing mixed shock. Prolonged hypoperfusion causes renal, hepatic, intestinal and neurological injury; when pharmacological support does not maintain perfusion, prompt evaluation for mechanical assistance aims to limit injury progression while the myocardium recovers.
Acute cellular rejection results from immune activity against donated tissue and may be asymptomatic or manifest as dysfunction, arrhythmias and low output. Antibody-mediated rejection chiefly involves the microvascular compartment and can present just as variably. Mixed forms are possible. Over time, recurrent episodes, persistent DSA and other factors may contribute to chronic injury, but the term chronic rejection must not become an indiscriminate explanation for all late deterioration: vasculopathy, fibrosis, valve disease and toxicity require specific characterisation.
Infections include surgical and healthcare-associated complications, reactivations, opportunistic diseases and community-acquired infections. Their timing depends on actual immunosuppression and prophylaxis; muted inflammatory signs do not exclude serious disease. Fever, diarrhoea, dyspnoea or neurological abnormalities require assessment that considers different pathogens and possible drug effects. Interactions between antimicrobials and immunosuppressants may turn treatment of infection into a risk of toxicity or underexposure, making coordination of prescriptions essential.
Cardiac allograft vasculopathy arises from multifactorial vascular injury and may cause diffuse ischaemia, infarction, arrhythmias, dysfunction and sudden death. Concentric distribution and microvascular involvement may be missed by assessment limited to focal stenoses. The absence of angina is not reassuring in a denervated heart. Surveillance aims to identify the process before advanced failure develops; therapeutic options depend on disease extent, anatomy, graft function and whether immunosuppression can be modified. Revascularising a focal lesion does not remove the diffuse component of the disease.
Late renal injury is often multifactorial: pre-existing nephropathy, ischaemic episodes, hypertension, diabetes and calcineurin-inhibitor toxicity may all contribute. Reducing a nephrotoxic drug may improve the balance, but excessive reduction in immune protection risks rejection. Hypertension, dyslipidaemia and post-transplant diabetes also increase cardiovascular and renal burden. Osteoporosis and fractures reflect interactions among pre-existing conditions, corticosteroids, inactivity and mineral disturbances. Prevention calls for longitudinal monitoring and targeted interventions because metabolic complications may accumulate even while cardiac function remains normal.
Skin cancers and post-transplant lymphoproliferative disorders are important surveillance concerns. Immunosuppression reduces immune control of abnormal cells and may favour the effects of oncogenic viruses; EBV is particularly important in some lymphoproliferative disorders. Risk magnitude varies with individual history and treatment duration and type. Sun protection, dermatological surveillance and appropriate screening accompany prompt assessment of lymphadenopathy, weight loss or persistent symptoms. Management may require immunosuppression changes and coordinated cancer therapy, balancing tumour control against graft survival.
Bradyarrhythmias and sinus node dysfunction may require temporary or permanent pacing; new atrial or ventricular arrhythmias call for investigation of rejection, ischaemia, electrolyte disturbances and other causes. Tricuspid regurgitation may be promoted by atrial geometry, right ventricular dysfunction or valve apparatus injury, including from repeated biopsies. Stenosis or abnormalities of vascular anastomoses and other surgical complications require dedicated anatomical evaluation. Finally, deteriorating adherence may link perceived toxicity, psychological difficulties and late rejection: effective follow-up seeks these problems before they appear as loss of transplanted-heart function.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.